CIMZIA® (certolizumab pegol) can make a difference, even in PsA and RA patients with previous TNF inhibitor experience
In the PsA study, CIMZIA delivered consistent results regardless of prior TNF inhibitor exposure1,5,10
RAPID-PsA STUDY
ACR20 response rates at week 121,5,10
- Primary efficacy measure was ACR20 response at week 12 for RAPID-PsA1,10
![In the RAPID-PsA Study, ACR20 response at week 12 for patients overall (primary endpoint) was 55% in the CIMZIA 200 mg combined doses (200 mg q2w + 400 mg q4w) group (n=273) compared with 24% for placebo q2w (n=136) (P<0.001). ACR20 response at week 12 for patients with prior TNF inhibitor experience was 54% in the CIMZIA 200 mg group (n=54) compared with 15% for placebo (n=26) (P<0.001). Reference: (1) CIMZIA® [prescribing information], Smyrna, GA: UCB, Inc.; 2013. (5) Data on file. UCB, Inc.; Smyrna, GA. (10) Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55.](/themes/custom/cimzia_hcp/assets/img/psa/priortnf_chart1.png)
- ITT-NRI: intent-to-treat nonresponder imputation.
- Prespecified secondary analysis of a primary endpoint; primary nonresponders excluded.
- Previous treatment with one TNF inhibitor biologic therapy was allowed, and 20% of patients had prior TNF inhibitor biologic exposure
- Distinct patient populations comparison between indications is NOT intended
Important Safety Information
- Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.
- Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus in patients who are chronic carriers of the virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.
In an RA study, CIMZIA delivered consistent results regardless of prior TNF inhibitor exposure12
REALISTIC STUDY*
ACR20 response rates at week 1212
- Primary efficacy measure was ACR20 response at week 12 for REALISTIC12
![In the RAPID 1 Study, ACR20 response at week 24 (primary endpoint) was 59% in the CIMZIA 200 mg q2w + MTX qw group (n=393) compared with 14% for placebo q2w + MTX qw (n=199) (P<0.001). Some CIMZIA RA patients experienced a rapid ACR20 response within 1 to 2 weeks. References: (1) CIMZIA® [prescribing information], Smyrna, GA: UCB, Inc.; 2013. (2) Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-3329. (5) Data on file. UCB, Inc.; Smyrna, GA.](/themes/custom/cimzia_hcp/assets/img/psa/priortnf_chart2.png)
- ITT-NRI: intent-to-treat nonresponder imputation.
- Patients were stratified at baseline by prior anti-tumor necrosis factor (TNF) experience (n=400 of 1063). Patients could have discontinued their prior TNF inhibitor for lack of efficacy, intolerance, or other reasons.
- Distinct patient populations comparison between indications is NOT intended
- See REALISTIC study design
- See AS-1 study design